Retatrutide represents a breakthrough in metabolic medicine as the first triple-agonist therapy targeting GLP-1, GIP, and glucagon receptors simultaneously. Unlike currently approved medications such as semaglutide or tirzepatide, this investigational drug has demonstrated weight loss results exceeding 24% in clinical trials, making proper dosing protocols essential for both safety and efficacy. Understanding the titration schedule can help you anticipate what to expect if this medication receives FDA approval.
The retatrutide dosing schedule follows a gradual escalation approach, typically starting at 2-4 mg per week and increasing every four weeks until reaching maintenance doses between 8-12 mg weekly, depending on your response and tolerability. This stepwise titration minimizes gastrointestinal side effects while allowing your body to adapt to the medication’s multi-receptor activity. The dosing strategy mirrors protocols used in phase 2 clinical trials, where participants achieved optimal results through careful dose management over 24-48 weeks.
Your specific dosing path will depend on several factors, including whether you’re using retatrutide primarily for weight loss or metabolic management. Clinical studies indicate that doses of 8 mg weekly provide substantial benefits with manageable side effects, while 12 mg doses produced the most significant weight reduction but with increased gastrointestinal symptoms. This guide breaks down each phase of the titration schedule, administration techniques, and what you need to know about managing this promising therapy.
Key Takeaways
- Retatrutide uses a gradual titration schedule starting at 2-4 mg weekly and escalating to 8-12 mg over several months
- The triple-agonist mechanism targeting GLP-1, GIP, and glucagon receptors produces superior weight loss compared to existing medications
- Proper dose escalation every four weeks minimizes gastrointestinal side effects while maximizing metabolic benefits
Fundamentals of Retatrutide and Mechanism of Action
Retatrutide operates through a triple-receptor mechanism that simultaneously activates GLP-1, GIP, and glucagon pathways. This approach differs substantially from single-agonist medications like semaglutide and dual-agonist options such as tirzepatide.
Triple Agonist Pathways Overview
Retatrutide functions as a triple-receptor agonist, engaging three distinct metabolic pathways at once. Unlike incretin mimetics such as Ozempic or Wegovy that target only the GLP-1 receptor, this compound activates GLP-1, GIP, and glucagon receptors simultaneously.
The triple agonist peptide design creates synergistic effects across appetite regulation, insulin secretion, and energy expenditure. Your body responds to these three signals together rather than sequentially. This multi-pathway activation is what distinguishes retatrutide from earlier incretin-based therapies.
Phase 2 clinical data demonstrated average body weight reductions of up to 24% over 48 weeks. The simultaneous receptor engagement appears to produce more substantial metabolic changes than single-pathway approaches.
Comparison With GLP-1 Analogs and Dual Agonists
The distinction between retatrutide and existing medications lies in receptor targeting breadth. Semaglutide (marketed as Ozempic and Wegovy) activates only GLP-1 receptors, focusing primarily on appetite suppression and insulin secretion.
Tirzepatide (Mounjaro and Zepbound) represents the dual-agonist category, targeting both GLP-1 and GIP receptors. This combination improves upon single-agonist results but still lacks glucagon pathway activation.
Retatrutide adds the glucagon receptor component, which influences energy expenditure and fat oxidation beyond what incretin hormones alone can achieve. The triple-receptor agonist mechanism may explain the enhanced weight reduction observed in clinical trials compared to both single and dual agonists.
Role of GLP-1, GIP, and Glucagon Receptors
Each receptor pathway contributes specific metabolic effects. The GLP-1 receptor primarily reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This pathway is well-established through medications like semaglutide.
The GIP receptor amplifies insulin response and may influence fat metabolism and nutrient storage patterns. GIP also modulates bone metabolism and central nervous system signaling related to food intake.
Glucagon receptors drive energy expenditure, promote fat oxidation, and increase metabolic rate. Glucagon activation traditionally raises blood glucose, but when combined with GLP-1 and GIP agonism, the effect shifts toward enhanced fat burning without problematic glucose elevation. This three-way receptor engagement creates a metabolic profile distinct from earlier incretin-based treatments.
Retatrutide Dosage Principles and Titration Protocols
Retatrutide dosing follows a structured escalation approach that balances receptor engagement with tolerability, typically starting at low exposure levels and increasing incrementally over several weeks. The titration protocol allows your system to adapt to the tri-agonist mechanism while minimizing potential side effects.
Standard Titration Schedule: Stepwise Escalation
The standard retatrutide dosage chart begins with 1 mg administered as a once weekly subcutaneous injection for the first two weeks. This initial exposure establishes baseline receptor engagement across GLP-1, GIP, and glucagon pathways.
After the first two weeks, you increase the retatrutide dose to 2 mg for weeks 3-4. This allows for gradual adaptation to the compound’s multi-receptor activity.
The protocol continues with 4 mg during weeks 5-8, followed by 8 mg during weeks 9-12. Each escalation step roughly doubles the previous dose, creating a logarithmic progression.
The maintenance phase typically reaches 12 mg from week 13 onward. Some protocols extend to 16 mg or higher depending on response and tolerability markers. Weekly injection timing should remain consistent throughout the entire titration period.
| Week Range | Retatrutide Dose | Purpose |
|---|---|---|
| 1-2 | 1 mg | Initial receptor engagement |
| 3-4 | 2 mg | Early adaptation phase |
| 5-8 | 4 mg | Progressive escalation |
| 9-12 | 8 mg | Therapeutic range entry |
| 13+ | 12 mg | Maintenance exposure |
Dose Escalation Strategies by Target Outcome
Your dose escalation approach should align with specific research endpoints. For body composition studies, slower titration with extended time at intermediate doses (4-8 mg) allows for better tracking of compositional changes.
Glycemic control protocols may emphasize faster progression to higher doses, as glucose-lowering effects often demonstrate clear dose-response relationships. Energy expenditure studies frequently maintain mid-range doses longer to isolate thermogenic contributions.
When comparing retatrutide to single-agonist compounds, parallel titration schedules help control for time-dependent variables. If you’re evaluating tolerability as a primary endpoint, conservative escalation with two-week intervals at each step provides clearer signal separation.
A retatrutide dosage calculator can help you model different escalation curves based on your target biomarkers, baseline measurements, and desired study duration.
Dose-Response and Optimization Considerations
The dose-response curve for retatrutide shows non-linear characteristics across different endpoints. Weight reduction effects typically plateau between 8-12 mg in most models, while metabolic markers may continue improving at higher exposures.
You should track multiple biomarkers simultaneously to identify your optimal dose range. Appetite suppression often manifests at lower doses than maximal weight loss, creating distinct response windows for different mechanisms.
Individual variability in dose-response can be substantial. Some subjects reach target outcomes at 8 mg while others require 12-16 mg to achieve comparable effects.
Dose optimization involves balancing efficacy markers against tolerability signals. If you observe sustained benefit without additional gains over two consecutive dose levels, you’ve likely identified the effective ceiling for that particular model or endpoint.
Titration Protocols for Different Research Models
Rodent models typically use body-weight-adjusted dosing, often expressed as micrograms per kilogram rather than fixed milligrams. You’ll need to establish allometric scaling factors when translating between model systems.
In vitro receptor assays use concentration-response curves rather than fixed dosing schedules, allowing you to map EC50 values across all three receptor targets simultaneously. These studies inform minimum effective exposure levels for in vivo work.
Long-duration metabolic studies (24+ weeks) may incorporate dose-hold periods where you maintain a specific retatrutide dose for 4-8 weeks before further escalation. This approach separates acute adaptation effects from sustained metabolic remodeling.
Comparative protocols evaluating retatrutide against GLP-1 monotherapy require parallel titration timelines with equivalent escalation intervals. You should match the frequency of once weekly subcutaneous injection across all treatment arms to control for administration-related variables.
Detailed Retatrutide Dosing Schedule for 2026
Retatrutide follows a structured weekly injection protocol that begins at 2 mg and can escalate to 12 mg based on individual response and tolerability. This graduated approach supports sustained retatrutide weight loss while managing gastrointestinal side effects common to multi-receptor agonists.
Initiation Phase and Starting Doses
Your treatment begins with 2 mg weekly for the first four weeks. This starting dose allows your body to adapt to retatrutide’s triple-receptor activity targeting GLP-1, GIP, and glucagon pathways simultaneously.
During this initiation period, you may experience mild nausea or reduced appetite as your system adjusts to the medication. These effects typically diminish as you continue treatment.
Some protocols may start at 4 mg weekly depending on your medical history and treatment goals. Your prescriber will determine the appropriate starting point based on factors including baseline weight, metabolic health markers, and prior experience with incretin-based therapies.
The initiation phase establishes tolerance before advancing to higher doses that produce more significant metabolic changes. Weekly subcutaneous injections should be administered on the same day each week for consistent therapeutic levels.
Escalation Phases (4 mg, 8 mg, 12 mg Protocols)
After four weeks at the starting dose, you advance to 4 mg weekly for weeks 5-8. This mid-range dose marks where measurable weight reduction becomes more apparent, though gastrointestinal effects may also intensify temporarily.
At weeks 9-12, your dose increases to 8 mg weekly. Clinical data shows this level produces substantial retatrutide weight loss while maintaining acceptable tolerability for most patients. Many individuals achieve meaningful results at this dose without requiring further escalation.
For maximum efficacy, particularly in retatrutide for obesity cases requiring aggressive intervention, the protocol advances to 12 mg weekly from week 13 onward. Phase 2 trials demonstrated average body weight reductions exceeding 24% at this dose over 48 weeks.
| Weeks | Dose | Expected Response |
|---|---|---|
| 1-4 | 2 mg | Adaptation period, minimal weight change |
| 5-8 | 4 mg | Initial weight reduction begins |
| 9-12 | 8 mg | Significant metabolic improvements |
| 13+ | 12 mg | Maximum therapeutic effect |
Not everyone requires progression to 12 mg. Your provider may pause escalation at 8 mg if you achieve target outcomes or experience persistent side effects.
Maintenance Dosing and Long-Term Use
Maintenance dosing begins once you reach your target dose and continues as long as treatment remains beneficial. Most patients maintain on either 8 mg or 12 mg weekly injections depending on individual response patterns.
Long-term data from ongoing Phase 3 studies suggests sustained weight management without significant rebound when continuing maintenance therapy. Your dose may be adjusted downward if you experience persistent adverse effects or upward if weight loss plateaus prematurely.
Regular monitoring during maintenance includes assessment of weight trends, metabolic markers, gastrointestinal tolerance, and cardiovascular parameters. Some patients maintain therapeutic benefit at reduced doses after achieving initial weight loss goals, though this approach requires close clinical supervision.
Treatment duration varies based on individual objectives. Current protocols support continuous use for 48 weeks or longer, with some trials extending beyond one year to evaluate durability of metabolic improvements and weight maintenance.
Administration Techniques and Reconstitution of Retatrutide
Proper reconstitution and injection technique ensure accurate dosing and safety when working with research-grade retatrutide. Research-grade peptides arrive as lyophilized powder that requires specific preparation steps before administration.
How to Reconstitute Retatrutide
Retatrutide comes as a lyophilized peptide in sealed vials that must be mixed with bacteriostatic water before use. This freeze-dried format maintains stability during storage and shipping.
Start by gathering your supplies: a retatrutide vial, bacteriostatic water, alcohol swabs, and sterile syringes. Remove both the peptide vial and bacteriostatic water from refrigeration and let them reach room temperature for 15-20 minutes.
Clean the rubber stoppers on both vials with alcohol swabs. Draw the appropriate amount of bacteriostatic water into your syringe based on your desired concentration. For a 10mg vial, 2ml of bacteriostatic water yields 5mg/ml concentration.
Insert the needle into the peptide vial at an angle and slowly inject the bacteriostatic water down the side of the glass. Never inject directly onto the powder. Gently swirl the vial in circular motions until the solution becomes clear. Do not shake vigorously as this can damage the peptide structure.
Store your reconstituted solution in the refrigerator at 36-46°F. Label the vial with the reconstitution date and concentration. Most reconstituted peptides remain stable for 28-30 days when properly stored.
Injection Administration Guidelines
Subcutaneous injection is the standard route for retatrutide administration. The abdomen, thighs, and upper arms are suitable injection sites with the abdomen being most commonly used.
Choose an injection site at least 2 inches away from your navel and any scars or moles. Clean the area with an alcohol swab and allow it to air dry completely. Draw your calculated dose into an insulin syringe, ensuring no air bubbles remain.
Pinch the skin to create a small fold. Insert the needle at a 45-90 degree angle depending on body composition. Push the plunger slowly and steadily, then hold for 5 seconds before withdrawing the needle.
Rotate injection sites with each administration to prevent tissue irritation and lipodystrophy. Keep a log of injection locations to maintain proper rotation. Use a new needle for each injection and dispose of used sharps in an approved container.
Research use only products require adherence to laboratory protocols. When you buy retatrutide for research purposes, verify the supplier provides certificates of analysis and proper documentation for research-grade peptides.
Managing Retatrutide Side Effects and Tolerability
Retatrutide’s side effects are primarily gastrointestinal and dose-dependent, requiring proactive management strategies during titration. Most adverse events peak during the first 2-4 weeks of treatment or following dose increases, then gradually diminish as your body adapts to the medication.
Gastrointestinal Adverse Events
Nausea is the most frequently reported side effect, affecting approximately 50-60% of participants in clinical trials at higher doses. This typically occurs within 24-72 hours after injection and resolves within a few days.
Diarrhea and vomiting affect 20-35% of users, with severity correlating directly to dose level. These symptoms are most common during titration phases when your dose increases from 4 mg to 8 mg weekly.
Constipation occurs in 15-25% of participants and may persist longer than other gastrointestinal side effects. The slowed gastric emptying that contributes to appetite suppression can also reduce bowel motility.
Serious gastrointestinal adverse events remain rare. Pancreatitis occurred in less than 1% of clinical trial participants, similar to placebo rates. However, you should discontinue retatrutide immediately if you experience severe, persistent abdominal pain radiating to your back.
Strategies to Minimize Nausea and GI Symptoms
Slow titration remains the most effective prevention strategy. Following the 4-week escalation schedule allows your body to gradually adapt to each dose level before advancing.
You can reduce nausea by taking these practical steps:
- Eat smaller, more frequent meals throughout the day
- Avoid high-fat, greasy, or heavily spiced foods
- Stay hydrated with clear fluids between meals
- Take anti-nausea medications like ondansetron if prescribed by your provider
For diarrhea management, increase soluble fiber intake and avoid caffeine and artificial sweeteners. Constipation responds well to increased water intake, dietary fiber, and gentle physical activity.
Timing your injection before bedtime may help you sleep through peak nausea periods. If symptoms become intolerable, your provider may extend the time at your current dose before escalating further.
Long-Term Safety Monitoring
Regular monitoring ensures early detection of potential complications beyond typical gastrointestinal side effects. Your healthcare provider should check liver enzymes (ALT and AST) every 3-6 months, as transient elevations occur in approximately 1% of users.
Pancreatic enzyme monitoring (lipase and amylase) is recommended for individuals with risk factors for pancreatitis, including history of gallstones or hypertriglyceridemia. Heart rate monitoring is also important, as retatrutide can cause modest increases that peak around 24 weeks.
Gallbladder ultrasound may be warranted if you develop right upper quadrant pain, as rapid weight loss increases gallstone formation risk. Report any persistent abdominal pain, yellowing of skin or eyes, or dark urine immediately.
Most adverse events decrease significantly after the first 8-12 weeks of treatment. Participants who tolerate the initial titration period typically experience improved tolerability at maintenance doses.
Clinical Outcomes: Weight Loss and Metabolic Benefits
Retatrutide’s triple-receptor mechanism produces substantial body weight reduction alongside meaningful improvements in appetite regulation and glucose metabolism. Clinical data reveal sustained weight loss exceeding most current therapies, with parallel benefits for insulin sensitivity and blood sugar control.
Body Weight Reduction and 24% Outcome Data
Phase 2 clinical trial data published in the New England Journal of Medicine demonstrates dose-dependent weight loss across all retatrutide treatment groups. At 48 weeks, participants receiving 12 mg weekly achieved 24.2% mean body weight reduction, while the 8 mg dose produced 22.8% reduction.
The percentage of participants achieving clinically significant weight loss thresholds increased with higher doses:
| Weekly Dose | Mean Weight Loss at 48 Weeks | Participants Achieving ≥15% Loss | Participants Achieving ≥20% Loss |
|---|---|---|---|
| 1 mg | 8.7% | 13% | 3% |
| 4 mg | 17.3% | 60% | 27% |
| 8 mg | 22.8% | 77% | 60% |
| 12 mg | 24.2% | 83% | 75% |
Weight loss outcomes remained consistent throughout the trial period, with most participants maintaining downward trajectory through week 48. Your individual results will depend on adherence, dose optimization, and lifestyle factors alongside medication therapy.
Appetite Suppression and Regulation
Retatrutide’s effects on appetite suppression occur through multiple pathways involving GLP-1 and GIP receptor activation in brain regions that control hunger signals. Participants in clinical trials reported reduced food cravings and earlier satiety during meals, contributing to spontaneous calorie reduction.
The medication slows gastric emptying, which prolongs feelings of fullness after eating. This mechanism supports appetite regulation without requiring conscious restriction or willpower-dependent dietary changes.
Energy expenditure may also increase through glucagon receptor activation, which promotes fat oxidation and thermogenesis. While the primary driver of weight management remains reduced caloric intake through appetite suppression, these metabolic effects contribute to overall body weight reduction.
Improvements in Glycemic Control and Insulin Sensitivity
Clinical data reveals significant improvements in glucose metabolism markers among participants with and without type 2 diabetes. Retatrutide enhanced insulin sensitivity through weight-dependent and weight-independent mechanisms, improving your body’s ability to regulate blood sugar levels.
Participants with type 2 diabetes experienced HbA1c reductions averaging 1.3-2.0 percentage points across dose groups. Fasting glucose levels decreased substantially, with many participants achieving normal blood sugar control by week 24.
The medication enhances glucose-dependent insulin secretion through GIP and GLP-1 pathways, meaning insulin release occurs primarily when blood sugar rises. This mechanism reduces hypoglycemia risk compared to older diabetes medications. Glucagon receptor activation also plays a role in glucose control by modulating hepatic glucose production, contributing to improved glycemic control throughout the day.
Retatrutide in the Context of Current and Future Research
Retatrutide represents a significant advancement in metabolic peptide research, with published Phase 2 data demonstrating weight reductions up to 24% and ongoing Phase 3 trials investigating its broader therapeutic potential. The evidence base continues to expand, positioning retatrutide alongside and potentially beyond current weight loss medications in terms of efficacy.
Summary of Major Clinical Trials and Evidence
The landmark Phase 2 trial published in the New England Journal of Medicine in 2023 established retatrutide’s efficacy profile across multiple dose levels. This 48-week study enrolled adults with obesity and evaluated doses ranging from 1 mg to 12 mg once weekly.
Results showed dose-dependent weight reduction:
| Dose | Average Weight Loss | Study Duration |
|---|---|---|
| 1 mg | 8.9% | 48 weeks |
| 4 mg | 17.1% | 48 weeks |
| 8 mg | 22.8% | 48 weeks |
| 12 mg | 24.2% | 48 weeks |
The 8 mg dose demonstrated a particularly favorable balance between efficacy and tolerability. Discontinuation rates due to adverse events ranged from 6-12% across dose groups, primarily related to gastrointestinal symptoms.
Phase 3 trials are currently underway, evaluating retatrutide in diverse populations including those with type 2 diabetes, cardiovascular risk factors, and varying degrees of obesity. These studies will provide data on long-term safety, cardiovascular outcomes, and sustained weight maintenance beyond one year.
Comparative Efficacy With Other Metabolic Peptides
Retatrutide research suggests superior weight loss compared to existing metabolic peptides and weight loss medications. GLP-1 receptor agonists like semaglutide achieve approximately 15-17% weight reduction at maximum doses, while retatrutide’s triple-agonist mechanism produced 24% reduction in Phase 2 trials.
The three-receptor approach distinguishes retatrutide from dual-agonist compounds. By activating GLP-1, GIP, and glucagon receptors simultaneously, retatrutide affects appetite regulation, insulin sensitivity, and energy expenditure through complementary pathways.
Traditional medications like metformin typically produce 2-3% weight loss, primarily through metabolic effects rather than direct appetite suppression. Even combination therapies with conventional agents rarely exceed 10% weight reduction, highlighting retatrutide’s potential as a more potent intervention.
Direct head-to-head trials comparing retatrutide with other metabolic peptides have not yet been published. Indirect comparisons suggest retatrutide may offer incremental benefit, though individual response variation remains significant across all medication classes.
Considerations for Research Protocol Design
Retatrutide research protocols emphasize gradual titration to optimize tolerability while reaching therapeutic doses. Studies typically initiate at 2 mg weekly with 4-week intervals between escalations, allowing physiological adaptation to each receptor activation level.
Your research protocol should account for several variables:
Titration timing affects both adherence and side effect burden. Slower escalation schedules may improve completion rates but extend time to maximum efficacy. Some protocols test whether flexible titration based on individual tolerance produces better outcomes than fixed schedules.
Endpoint selection varies by research question. Weight loss remains the primary endpoint in obesity trials, but metabolic parameters (HbA1c, lipids, blood pressure) and patient-reported outcomes (quality of life, eating behaviors) provide important secondary data.
Population characteristics influence dosing requirements. Studies in participants with higher baseline BMI, longer diabetes duration, or previous medication exposure may require adjusted protocols or stratified analysis to capture treatment effects accurately.
Monitoring protocols in retatrutide research typically include regular assessment of gastrointestinal symptoms, vital signs, and laboratory markers including lipase and gallbladder imaging in some studies.
Frequently Asked Questions
Retatrutide dosing typically begins at 1-2 mg weekly with gradual increases every 4 weeks, though individual titration schedules vary based on tolerance and response. Clinical protocols suggest maintenance doses of 8-12 mg weekly after completing the escalation phase.
What is the starting dosage for Retatrutide in a titration schedule?
Most preclinical studies and clinical protocols begin with 1 mg once weekly. This starting dose allows your body to adapt to the medication while minimizing gastrointestinal side effects.
Some protocols may initiate treatment at 2 mg weekly depending on individual patient factors and provider assessment. You typically remain at the starting dose for 2-4 weeks before any increase occurs.
The conservative starting approach reduces the risk of nausea and other adverse effects that become more common with higher initial doses.
How do you adjust the dosage of Retatrutide for weight-based treatment plans?
Retatrutide dosing is not calculated based on body weight in current clinical protocols. The medication follows a standardized titration schedule regardless of your starting weight.
Your healthcare provider determines dose adjustments based on tolerance, side effect severity, and weight loss progress rather than a weight-based formula. This differs from some other medications that require weight-based calculations.
The focus remains on finding your optimal therapeutic dose within the established range of 1-12 mg weekly. Individual response to treatment guides progression through the titration schedule.
What is the recommended titration schedule for patients beginning Retatrutide therapy?
The standard titration protocol increases doses every 4 weeks. You start at 1 mg weekly for weeks 1-4, then advance to 2 mg for weeks 5-8.
The schedule continues with 4 mg during weeks 9-12, followed by 6 mg for weeks 13-16. Most patients reach 8 mg by week 17, which serves as a common maintenance dose.
Some individuals continue escalating to 12 mg weekly based on tolerance and treatment goals. Your provider may extend any dose level by an additional 2-4 weeks if you experience significant side effects.
Can you provide a dosage chart for incrementally increasing Retatrutide doses?
Week 1-4: 1 mg once weekly. Week 5-8: 2 mg once weekly.
Week 9-12: 4 mg once weekly. Week 13-16: 6 mg once weekly.
Week 17-20: 8 mg once weekly. Week 21 and beyond: 8-12 mg once weekly for maintenance.
This schedule represents the Phase 2 clinical trial protocol. Your actual progression may differ based on individual factors and provider recommendations.
How is Retatrutide dosing frequency determined for chronic administration?
Retatrutide is administered once weekly due to its extended half-life of approximately 6 days. This pharmacokinetic profile maintains steady therapeutic levels between doses.
You should inject on the same day each week to maintain consistent medication levels. The timing during that day can vary based on your preference and schedule.
Once-weekly dosing improves adherence compared to daily medications. The long-acting formulation eliminates the need for more frequent administration.
When titrating Retatrutide dosage, what are the signs that indicate a need for adjustment?
Severe or persistent nausea lasting more than 48 hours suggests you may need to remain at your current dose longer. Frequent vomiting that prevents adequate fluid intake requires immediate provider consultation.
Signs you may be ready to increase include minimal side effects at your current dose and continued weight loss progress. A plateau in weight loss after 4-6 weeks at the same dose may indicate readiness for escalation.
Rapid heart rate increases above 20 beats per minute from baseline warrant dose evaluation. Severe abdominal pain or signs of pancreatitis require stopping the medication and seeking immediate medical attention.
